A new study shows the first promising therapy that can impact solid cancer tumors. The HPV-targeted adoptive T-cell therapy, boosts a cervical cancer patient's natural immune response to the virus by removing T-cells from the patient, growing it and putting them back in.
A new study shows the first promising therapy that can impact solid cancer tumors. The HPV-targeted adoptive T-cell therapy, boosts a cervical cancer patient's natural immune response to the virus by removing T-cells from the patient, growing it and putting them back in.
Share this Article
Recommended